Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Fulcrum Therapeutics Inc(FULC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for FULC
09/15/2026: FULC (1-star) is currently NOT-A-BUY. Pass it for now.
Fulcrum Therapeutics is a clinical-stage biotechnology company developing small-molecule therapies for rare, genetically defined disorders. The company’s primary strength is its FulcrumSeek discovery engine, which aims to identify targets for diseases previously considered difficult to treat. Its current growth story is anchored on advancing its lead candidate, losmapimod, through late-stage clinical trials for FSHD. Key risks for investors include the binary nature of clinical trial outcomes, the lack of commercial revenue, and intense competition within the orphan disease space. This stock is best suited for risk-tolerant growth investors, and monitoring future clinical data readouts and regulatory milestones remains critical for evaluating long-term potential.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Fulcrum is a high-risk, high-reward play suitable for those willing to accept volatility in exchange for potential breakthroughs in rare diseases. |
| Momentum investor | Mixed fit | Momentum investors may find opportunities around clinical readout dates, provided the market trend aligns with positive sentiment. |
| Value investor | Weak fit | As a clinical-stage company with no revenue, standard value metrics do not currently apply. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses entirely on reinvestment for growth. |
| Low-risk investor | Weak fit | The significant binary risk associated with clinical trial results makes this unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to news about clinical trials and regulatory decisions. |
| Valuation risk | Medium / high | Valuation is speculative and heavily dependent on the projected commercial success of unproven pipeline assets. |
| Competition risk (Rare Disease Therapies) | Medium | The company faces competition from well-funded firms developing alternative genetic therapies. |
| Business quality | Medium | While the platform is robust, the company is still establishing its commercial capabilities. |
| Dividend income | Low / none | There is no dividend policy, making the stock inappropriate for income-seeking investors. |
| Execution risk | High | Success depends entirely on the ability to navigate complex clinical, regulatory, and manufacturing hurdles. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -18.87% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 289.17M USD | Price to earnings Ratio - | 1Y Target Price 3.5 |
Price to earnings Ratio - | 1Y Target Price 3.5 | ||
Volume (30-day avg) 1.6M shares | Beta 2.58 | 52 Weeks Range 2.83 - 15.74 | Updated Date 09/15/2026 |
52 Weeks Range 2.83 - 15.74 | Updated Date 09/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.21 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Biopharmaceutical R&D | Development of clinical-stage candidates for rare diseases. | The company does not generate revenue yet; investors are betting on the eventual success of its drug pipeline. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -23.25M | Price to Sales(TTM) 2.66 |
Enterprise Value -23.25M | Price to Sales(TTM) 2.66 | ||
Enterprise Value to Revenue 117.4 | Enterprise Value to EBITDA -3.09 | Shares Outstanding 76.30M | Shares Floating 63.49M |
Shares Outstanding 76.30M | Shares Floating 63.49M | ||
Percent Insiders 3.35 | Percent Institutions 103.4 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Fulcrum Therapeutics Inc
Exchange NASDAQ | Headquarters Cambridge, MA, United States | ||
IPO Launch date 2019-07-18 | CEO, President & Director Mr. Alexander C. Sapir | ||
Sector Healthcare | Industry Biotechnology | Full time employees 9 | Website https://www.fulcrumtx.com |
Full time employees 9 | Website https://www.fulcrumtx.com | ||
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.